期刊
DIABETES CARE
卷 33, 期 10, 页码 2178-2180出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc10-0494
关键词
-
资金
- Diabetes UK BDA [08/0003702]
- Novo Nordisk
- Asahi Kasei Pharma
- Bayer Healthcare
- Bayer Schering Pharma
- Bristol-Myers Squibb
- GlaxoSmithKline
- Merck
- Merck Serono
- Novartis
- Pfizer
- Sanofi-aventis
- Amylin
- Eli Lilly
OBJECTIVE - To explore patients' and health professionals experiences of initiating insulin as pan of the Treating To Target in Type 2 Diabetes (4-T) randomized controlled trial. RESEARCH DESIGN AND METHODS - Interviews were conducted with 45 trial participants and 21 health professionals and thematically analyzed. RESULTS - Patients were generally psychologically insulin receptive when approached to participate in the 4-T trial. Their receptiveness arose largely from their personal experiences observing intensifying prior treatments and deteriorating blood glucose control over time, which led them to engage with and accept the idea that their diabetes was progressive. Health professionals also fostered receptiveness by drawing on their clinical experience 10 manage patients' anxieties about initiating insulin. CONCLUSIONS - Previous studies may have overemphasized die problem of psychological insulin resistance and overlooked factors and treatment experiences that may promote insulin receptiveness among type 2 patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据